FDA Accepted Fylrevy Application for Menopause Therapy
The FDA is now reviewing an oral estrogen treatment that could offer a new hormonal option for women managing menopause symptoms.
Updated on Oct. 14, 2026 in Women’s Health
Live Poll
Do you believe more options for menopausal hormone therapy improve your quality of life?
The FDA has accepted the application for Fylrevy, an orally administered estrogen therapy, to treat moderate to severe vasomotor symptoms associated with menopause. If approved, this would mark the first menopausal hormone therapy containing estetrol available on the U.S. market.
Why it matters
This application brings a new category of hormone therapy closer to the U.S. market, potentially providing an alternative treatment pathway for managing vasomotor symptoms. The review process will determine if this therapy meets regulatory standards for use by the American public.
The application for Fylrevy is based on the therapeutic profile of its primary component, estetrol, which currently holds marketing authorization in several European nations. The FDA is currently assessing the data package to determine if the drug warrants approval for U.S. patients.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and medical devices.
European Commission
The executive branch of the European Union responsible for granting marketing authorizations for medicinal products across the European Economic Area.
The details
Fylrevy is an oral estrogen therapy designed to manage moderate to severe vasomotor symptoms, such as hot flashes, that commonly occur during menopause. It utilizes estetrol, a specific type of estrogen, as its primary active ingredient. This therapy is already available in Hungary, the Czech Republic, Slovakia, Finland, and Sweden.
Timeline
March 2026: The European Commission granted marketing authorization for Fylrevy.
Q3 2027: The FDA is expected to complete its review of the drug application.
Health Landscape
The potential arrival of Fylrevy represents an expansion of the current menopausal hormone therapy market. It follows the established FDA review process required for any novel pharmaceutical product seeking entry to the United States market.
If you are managing moderate to severe vasomotor symptoms, you may want to monitor the FDA review progress to see if new treatment options become available. Discuss your current symptom management plan and any new therapy options with your physician to determine what is appropriate for your health.
The takeaway
The FDA review of Fylrevy signals a potential addition to the available treatments for menopausal vasomotor symptoms. If you are exploring hormone therapy, keep a record of your symptom frequency and severity to share during your next visit with your doctor.
What happens next
The FDA is expected to complete its review of the Fylrevy application by the third quarter of 2027.
Further reading
For more on managing transitions, see our comprehensive guide on Women’s Health.
Live Poll
Do you believe more options for menopausal hormone therapy improve your quality of life?
